Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

14.94 -0.16 (-1.06%)
Streaming Delayed Price Updated: 2:08 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,882
Open 15.01
Bid (Size) 14.90 (100)
Ask (Size) 15.02 (100)
Prev. Close 15.10
Today's Range 14.94 - 15.33
52wk Range 11.51 - 19.50
Shares Outstanding 871,256,270
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
HUTCHMED to Announce 2025 Final Results
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
From HUTCHMED (China) Limited
Via GlobeNewswire

Performance

YTD
+9.5%
+9.5%
1 Month
-4.4%
-4.4%
3 Month
+2.8%
+2.8%
6 Month
-5.9%
-5.9%
1 Year
+8.9%
+8.9%

More News

Read More
News headline image
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday ↗
Via Benzinga
News headline image
Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Appointment of Acting Chief Executive Officer
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Reports 2025 Interim Results
From HUTCHMED (China) Limited
Via GlobeNewswire

Frequently Asked Questions

Is HUTCHMED (China) Limited - American Depositary Shares publicly traded?
Yes, HUTCHMED (China) Limited - American Depositary Shares is publicly traded.
What exchange does HUTCHMED (China) Limited - American Depositary Shares trade on?
HUTCHMED (China) Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for HUTCHMED (China) Limited - American Depositary Shares?
The ticker symbol for HUTCHMED (China) Limited - American Depositary Shares is HCM on the Nasdaq Stock Market
What is the current price of HUTCHMED (China) Limited - American Depositary Shares?
The current price of HUTCHMED (China) Limited - American Depositary Shares is 14.94
When was HUTCHMED (China) Limited - American Depositary Shares last traded?
The last trade of HUTCHMED (China) Limited - American Depositary Shares was at 02/19/26 02:08 PM ET
What is the market capitalization of HUTCHMED (China) Limited - American Depositary Shares?
The market capitalization of HUTCHMED (China) Limited - American Depositary Shares is 13.02B
How many shares of HUTCHMED (China) Limited - American Depositary Shares are outstanding?
HUTCHMED (China) Limited - American Depositary Shares has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.